Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
07 sept. 2022 18h05 HE
|
Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...
Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022
25 août 2022 07h00 HE
|
Elevar Therapeutics
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Global Culture Media Market Anticipated to Generate a Revenue of $5,398.6 Million and Rise at a CGAR of 7.7% over the Analysis Timeframe 2020-2027 [230-Pages] | Research Dive
22 août 2022 09h07 HE
|
Research Dive
New York, USA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global culture media market is envisioned to generate a revenue of $5,398.6 million and grow at...
Cell Culture Reagents Market Worth $11.04 billion by 2029 - Exclusive Report by Meticulous Research®
08 août 2022 11h00 HE
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Aug. 08, 2022 (GLOBE NEWSWIRE) -- According to a new market research report, ‘Cell Culture Reagents Market by Product (Growth Factors and Cytokines, Supplements,...
Sunshine Biopharma Files Its Second Quarter Report With the SEC
04 août 2022 08h00 HE
|
Sunshine Biopharma Inc.
MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and...
Across the U.S., Cancer Survivors, Caregivers, and their Loved Ones will Climb for a Cure
03 août 2022 10h46 HE
|
Fight Colorectal Cancer
Springfield, Mo., Aug. 03, 2022 (GLOBE NEWSWIRE) -- On August 6 and 7, Fight Colorectal Cancer (Fight CRC), a national nonprofit organization, and advocates from across the country will be hosting...
Cell Culture Market Worth $48.63 Billion by 2029 - Exclusive Report by Meticulous Research®
27 juil. 2022 09h00 HE
|
Meticulous Market Research Pvt. Ltd.
Redding, California, July 27, 2022 (GLOBE NEWSWIRE) -- According to a new market research report, ‘Cell Culture Market by Product [Consumables (Media, Reagents, Sera, Cell Lines), Equipment...
Theralase Expands Intellectual Property Portfolio
28 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Research - One of the Top 10 Most Downloaded Papers
24 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Cell Invasion and Migration Assay Market Research Report 2022-2035 with Profiles of Abcam, BioVision, Enzo Life Sciences, MilliporeSigma, R&D Systems, Sigma-Aldrich
23 juin 2022 04h03 HE
|
Research and Markets
Dublin, June 23, 2022 (GLOBE NEWSWIRE) -- The "Cell Invasion and Migration Assay Market by Type of Assay, Application Areas, Detection Method Used and Key Geographical Regions: Industry Trends and...